Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Poziotinib in NSCLC with EGFR or HER2 Exon 20 Insertions
2020-005213-40Phase 2Terminated
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of poziotinib in non-small cell lung cancer (NSCLC), sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoint: Continued monitoring of patients deriving clinical benefit from poziotinib. Started Aug 2021; status: terminated.
02
Drugs
poziotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-005213-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005213-40.